[1]徐海青,段俊,吴边.全身骨显像诊断前列腺癌骨转移与PSA水平及病理分级的相关性研究[J].国际放射医学核医学杂志,2011,35(1):34-37.[doi:10.3760/cma.j.issn.1673-4114.2011.01.010]
　XU Hai-qing,DUAN Jun,WU Bian.Study of relationship between the bone imaging, level of PSA and pathology grade in diagnosis of prostate carcinoma bone metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):34-37.[doi:10.3760/cma.j.issn.1673-4114.2011.01.010]
点击复制

全身骨显像诊断前列腺癌骨转移与PSA水平及病理分级的相关性研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
35
期数:
2011年第1期
页码:
34-37
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Study of relationship between the bone imaging, level of PSA and pathology grade in diagnosis of prostate carcinoma bone metastasis
作者:
徐海青;  段俊;  吴边
安徽省安庆市立医院核医学科, 安徽 246003
Author(s):
XU Hai-qing;  DUAN Jun;  WU Bian
Deportment of Nuclear Medicine, Anqing City Hospital, Anqing 246003, China
关键词:
前列腺肿瘤; 肿瘤转移; 骨; 99m锝美罗酸盐; 前列腺特异抗原
Keywords:
Prostatic neoplasms; Neoplasm metastasis; Bone; Technetium Tc 99m medronate; Prostate-specific antigen
DOI:
10.3760/cma.j.issn.1673-4114.2011.01.010
摘要:
目的 探讨核素全身骨显像诊断前列腺癌骨转移与血清前列腺特异性抗原(PSA)水平及前列腺癌病理分级的关系,并研究前列腺癌发生骨转移的规律和特点。方法 对107例前列腺癌患者术前用放免法测定其血清PSA水平,并进行99Tcm-亚甲基二瞵酸盐全身骨显像,术后对其进行病理分级,分析前列腺癌骨转移与3种方法检查结果的相关性。结果 107例前列腺癌患者全身骨显像发现49例发生骨转移,占45.8%(49/107),其中,不同病理分组之间的骨转移发生率差异有统计学意义(χ2=15.41,P<0.01)。前列腺癌分化程度越低,骨转移发生率越高;随着血清中PSA水平的升高,骨转移的发生率明显增加,PSA>20μg/L者有骨转移可能,PSA>60μg/L者骨转移的可能性极大。结论 前列腺癌患者骨转移发生率与前列腺癌的分化程度、血清PSA水平有一定的关系。低分化者或PSA>20μg/L者,骨转移发生率高。对于初诊的前列腺癌患者,PSA<20μg/L者应密切随访其PSA水平变化;PSA>20μg/L者应行骨显像以确诊;PSA>60μg/L者临床可诊断为骨转移。
Abstract:
Objective To investigate the relationship between the level of serum prostate-specific antigen (PSA), pathology grade and bone imaging in diagnosis of bone metastasis in prostatic carcinoma.Methods Serum PSA, whole body bone imaging with 99Tcm-methylene diphosphonate, pathology grade in 107 cases of prostatic carcinoma were retrospectively reviewed as to their correlation with bone metastasis. Results Fourty-nine of 107 cases demonstrated bone metastasis by whole body bone imaging. There were significant difference in bone metastasis incidence rate among high differentiation group, middle differentiation group and low differentiation group. The results showed that when PSA<20 μg/L, the possibility of bone metastasis was extremely low and follow-up studies were reuired. When serum PSA>20 μg/L, bone metastasis should be considered and bone imaging was necessary. Conclusions There were some relationship among the level of PSA, pathology grade and bone metastasis. The possibility of bone metastasis became high when PSA>20μg/L. If PSA>60 μg/L, a clinical diagnosis of bone metastasis might be made.

参考文献/References:

[1] Armstrong AJ, Tannock IF, do Wit R,et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer, 2010, 46(3):517-525.
[2] 罗勇,张林琳,贺大林.前列腺癌的骨转移倾向.国外医学泌尿系统分册,2004, 24(2):145-149.
[3] Chiu JS, Wang YF, Su YC,et al. Artificial neural network to predict skeletal metastasis in patients with prostate cancer. J Med Syst, 2009, 33(2):91-100.
[4] Gomes RR Jr, Buttke P, Paul EM,et al. Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation. Clin Exp Metastasis, 2009, 26(7):641-651.
[5] Klotz L. Active surveillance for prostate cancer:a review. Curr Urol Rep, 2010, 11(3):165-171.
[6] Chybowski FM, Bergstralh EJ,Oesterling JE. The effect of digital rectal examination on the serum prostate specific antigen concen-tration:results of a randomized study. J Urol, 1992, 148(1):83-86.
[7] Schulman C. PSA:an update.Arch Ital Urol Androl, 2006, 78(4):161-162.
[8] Henry N, Sebe P, Cussenot O.Inappropriate treatment of prostate cancer caused by heterophilic antibody interference. Nat Clin Pract Urol, 2009, 6(3):164-167.
[9] Schilling D, Hennenlotter J, Munz M,et al. Interpretation of the prostate cancer gene 3 in reference to the individual clinical back-ground:implications For daily practice.Urol Int, 2010, 85(2):159-165.
[10] Maeda H, Yonou H, Yano K, et al. Prostate-specific antigen en-hances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5. Biochem Biophys Res Commun, 2009, 381(3):311-316.
[11] Köllermann J, Weikert S, Schostak M,et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol, 2008, 26(30):4928-933.

相似文献/References:

[1]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
　Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[2]张胤,陈跃.18F-氟化钠PET/CT诊断肿瘤骨转移应用进展[J].国际放射医学核医学杂志,2015,39(1):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
　Zhang Yin,Chen Yue.Application progress of 18F-NaF PET/CT in the diagnosis of neoplasm metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
[3]刘辰,杨悦,张雪宁,等.MRI和1997年版Partin表对前列腺癌病理特征预测准确性的对比研究[J].国际放射医学核医学杂志,2015,39(2):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
　Liu Chen,Yang Yue,Zhang Xuening,et al.Accuracy of MRI and 1997 edition of Partin tables in predicting the pathological features of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
[4]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
　Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
[5]刘雪辉,李洪均,于鸿煦.SPECT/CT融合显像对可疑骨转移灶的诊断效能[J].国际放射医学核医学杂志,2015,39(3):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
　Liu Xuehui,Li Hongjun,Yu Hongxu.Diagnostic efficacy of SPECT/CT fusion imaging in assessing possible bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
[6]张晖,段清,卓娜,等.经直肠超声引导下“6+X”点法前列腺穿刺活检诊断前列腺癌的临床价值分析[J].国际放射医学核医学杂志,2015,39(4):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
　Zhang Hui,Duan Qing,Zhuo Na,et al.Meta-analysis of the diagnostic value of transrectal ultrasound-guided “6+X” points biopsy in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
[7]张龙敏,刘爱连.前列腺癌MRI诊断技术研究进展[J].国际放射医学核医学杂志,2014,38(1):53.[doi:10.3760/cma.j.issn 1673-4114.2014.01.011]
　Zhang Longmin,Liu Ailian.Advances in MRI diagnosis of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):53.[doi:10.3760/cma.j.issn 1673-4114.2014.01.011]
[8]高平,王茜,赵赟赟,等.99Tcm-MDP SPECT/CT显像用于骨肉瘤肺转移的诊断[J].国际放射医学核医学杂志,2014,38(3):148.[doi:10.3760/cma.j.issn.1673-4114.2014.03.002]
　Gao Ping,Wang Qian,Zhao Yunyun,et al.99Tcm-MDP SPECT/CT used in diagnosis of pulmonary metastasis from osteosarcoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):148.[doi:10.3760/cma.j.issn.1673-4114.2014.03.002]
[9]刘辰,杨悦,张雪宁,等.CT/MRI图像融合在前列腺癌IMRT中的应用进展[J].国际放射医学核医学杂志,2014,38(4):247.[doi:10.3760/cma.j.issn.1673-4114.2014.04.010]
　Liu Chen,Yang Yue,Zhang Xuening,et al.CT/MRI image fusion in intensity modulated radiation therapy for prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):247.[doi:10.3760/cma.j.issn.1673-4114.2014.04.010]
[10]凌彩霞,肖国有.SPECT/CT骨断层显像及在恶性肿瘤骨转移诊断中的临床价值[J].国际放射医学核医学杂志,2014,38(4):275.[doi:10.3760/cma.j.issn.1673-4114.2014.04.016]
　Ling Caixia,Xiao Guoyou.The clinical value of SPECT/CT bone tomography in the diagnosis of malignant tumor metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):275.[doi:10.3760/cma.j.issn.1673-4114.2014.04.016]
[11]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
　Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[12]桂继琮,刘兴党.镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展[J].国际放射医学核医学杂志,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
　Gui Jicong,Liu Xingdang.Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
[13]袁超,李卫鹏,胡永全,等.89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察[J].国际放射医学核医学杂志,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
　YUAN Chao,LI Wei-peng,HU Yong-quan,et al.Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
[14]耿峻,吴兴勇,胡德胜,等.前列腺癌48例患者全身核素骨显像的临床价值[J].国际放射医学核医学杂志,2007,31(4):238.

备注/Memo

备注/Memo:
收稿日期:2010-10-20。
通讯作者:徐海青(Email:xnqinghcyixuc@yahoo.cn)
更新日期/Last Update: 1900-01-01